Sun Pharma Advanced Research (SPARC) Stock Soars After US Court Ruling on Sezaby PRV – What the 30% Two‑Day Rally on 3 December 2025 Really Means

On 2 December 2025, the stock hit the 20% upper circuit at around ₹161.10, after a US court delivered a favourable ruling in a long‑running dispute over a Priority Review Voucher linked to its neonatal seizure drug, Sezaby. Intra‑day data show around 27.7 million shares changing hands on the BSE, representing roughly 8.5% of the company’s equity, far above normal volumes. Business Standard+1